Skip to main content

Aadi Bioscience Inc

For the period ended Dec 31, 2023. Filed Mar 13, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 13, 2024

WHWK$3.13+3.6%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 16. Form of 10-K Summary

We may voluntarily include a summary of information required by Form 10-K under this Item 16. We have elected not to include such summary information.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

AADI BIOSCIENCE, INC.
Date: March 13, 2024By:/s/ David J. Lennon
David J. Lennon, Ph.D.
Chief Executive Officer and President(Principal Executive Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David J. Lennon, Ph.D., Scott Giacobello and Stephen Rodin, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

NameTitleDate
/s/ David J. LennonChief Executive Officer and President and Director(Principal Executive Officer)March 13, 2024
David J. Lennon, Ph.D.
/s/ Scott GiacobelloChief Financial Officer(Principal Financial and Accounting Officer)March 13, 2024
Scott Giacobello
/s/ Caley CasteleinChairmanMarch 13, 2024
Caley Castelein, M.D.
/s/ Behzad AghazadehDirectorMarch 13, 2024
Behzad Aghazadeh, Ph.D.
/s/ Anupam DalalDirectorMarch 13, 2024
Anupam Dalal, M.D.
/s/ Neil DesaiDirector; Executive ChairmanMarch 13, 2024
Neil Desai, Ph.D.
/s/ Karin HehenbergerDirectorMarch 13, 2024
Karin Hehenberger, M.D., Ph.D.
/s/ Mohammad HirmandDirectorMarch 13, 2024
Mohammad Hirmand, M.D.
/s/ Richard MarounDirectorMarch 13, 2024
Richard Maroun, J.D.
/s/ Emma ReeveDirectorMarch 13, 2024
Emma Reeve
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.